You know, like Shkreli is morally, but with money.
After Shkreli purchased a majority stake in the struggling company and took over as its CEO in November, KaloBios’s fortunes appeared to be improving. But Shkreli, who rose to prominence after monstrously jacking up the price of an AIDS drug sold through another company he ran, Turing Pharmaceuticals, was indicted on securities fraud charges in mid-December, prompting KaloBios to fire him. Shortly thereafter, Nasdaq staff delisted KaloBios’s shares from public trading.
And, while the world was savoring Shkreli’s slouchy, gray-hoodied, post-bail walk of shame, KaloBios was apparently preparing to file for bankruptcy, which it formally declared Tuesday.
Though the Delaware-based company was by no means a major employer, it’s never all that satisfying to see a company with any number of innocent employees go under. On the other hand, it’s hard not to read the continued downward spiral of Shkreli and his bizarre ubermensch routine as a certain brand of poetic justice.